by Sustainable Pulse 
For the past 35 years Monsanto has known of the link between glyphosate and cancer, but has systematically worked to cover it up through scientifically fraudulent methods in its safety testing research programme. This is the most significant conclusion to be drawn from a new research paper  published in the Journal of Biological Physics and Chemistry and now available online.
For the first time the authors, Dr. Anthony Samsel and Dr. Stephanie Seneff, present in tabulated form the data contained in secret Monsanto studies conducted in the period 1980 – 1990 which showed unequivocally that animals exposed to different quantities of glyphosate in their food supply developed tumorigenic growth in multiple organs.
Both Monsanto and the American EPA knew of these and other deleterious effects, but the EPA agreed to refer to these early studies as “trade secrets” and prevented public scrutiny. The results were considered inconvenient, and so they were ignored. To make matters worse, the EPA then agreed to further Monsanto-sponsored studies which used inappropriate control group data to create “experimental noise” and to mask carcinogenic and other effects in the animal test groups. Other fraudulent practices have also been subsequently revealed, including the non-reporting of test group deaths, the fabrication of data tables, and the falsification of experimental data.
Dr Samsel is the first independent researcher to have been given access to the full Monsanto / EPA dossier of research reports, and the new paper itemises the key research findings in these early papers and presents a number of detailed appendices of the results.
Read the Full Article at Sustainable Pulse .
We Lost the War on Cancer – Review of Alternative Cancer Therapies
We have lost the war on cancer. At the beginning of the last century, one person in twenty would get cancer. In the 1940s it was one out of every sixteen people. In the 1970s it was one person out of ten. Today one person out of three gets cancer in the course of their life.
The cancer industry is probably the most prosperous business in the United States. In 2014, there will be an estimated 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in the US. $6 billion of tax-payer funds are cycled through various federal agencies for cancer research, such as the National Cancer Institute (NCI). The NCI states that the medical costs of cancer care are $125 billion, with a projected 39 percent increase to $173 billion by 2020.
The simple fact is that the cancer industry employs too many people and produces too much income to allow a cure to be found. All of the current research on cancer drugs is based on the premise that the cancer market will grow, not shrink.
John Thomas explains to us why the current cancer industry prospers while treating cancer, but cannot afford to cure it in Part I. In Part II, he surveys the various alternative cancer therapies that have been proven effective, but that are not approved by the FDA.